---
title: "What's Going On With MannKind Stock Friday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277234995.md"
description: "MannKind Corp. (NASDAQ: MNKD) reported strong Q4 and FY 2025 results, with earnings per share of one cent and sales of $111.955 million, exceeding expectations. The company highlighted growth in royalties and product sales, particularly with Furoscix. However, the stock is currently trading below its moving averages, indicating a bearish trend. Analysts maintain a Buy rating with an average price target of $8.38, while the next earnings report is expected on May 7, 2026, with an EPS estimate of 2 cents."
datetime: "2026-02-27T17:30:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277234995.md)
  - [en](https://longbridge.com/en/news/277234995.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277234995.md)
---

# What's Going On With MannKind Stock Friday?

**MannKind Corporation** (NASDAQ:MNKD) reported its fourth-quarter and full-year 2025 financial results on Friday.

The company reported fourth-quarter adjusted earnings per share of one cent, in line with the Street view. Quarterly sales of $111.955 million outpaced the Street view of $97.604 million.

MannKind reported total revenues for the fourth quarter and full year 2025 rose due to increases in revenue from royalties, collaborations, and commercial product sales.

The CEO highlighted the addition of Furoscix as a significant boost to their cardiometabolic franchise, while Afrezza and UT-related revenues continue to show sustained growth.

MannKind exited the quarter with cash and equivalents worth $74.882 million.

## Technical Analysis

The stock is currently trading 9.8% below its 20-day simple moving average (SMA) and 4.1% below its 100-day SMA, indicating a bearish trend in the short to medium term. Over the past 12 months, shares have decreased significantly and are currently positioned closer to their 52-week lows than highs.

The RSI is at 44.45, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at 0.15, below its signal line at 0.22, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should be cautious in their approach.

-   **Key Resistance**: $4.00
-   **Key Support**: $2.50

## Earnings & Analyst Outlook

Looking further out, the next major catalyst for the stock arrives with the May 7, 2026, earnings report.

-   **EPS Estimate**: 2 cents (Down from 7 cents)
-   **Revenue Estimate**: $98.62 million (Up from $78.35 million)
-   **Valuation**: P/E of 32.3x (Indicates premium valuation)

**Analyst Consensus & Recent Actions:** The stock carries a Buy Rating with an average price target of $8.38. Recent analyst moves include:

-   **HC Wainwright & Co.**: Buy (Lowers Target to $8.00) (Feb. 27)

**MNKD Price Action:** MannKind shares were up 0.77% at $3.26 at the time of publication on Friday, according to Benzinga Pro data.

_Image via Shutterstock_

### Related Stocks

- [MNKD.US](https://longbridge.com/en/quote/MNKD.US.md)

## Related News & Research

- [MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Brokerages](https://longbridge.com/en/news/280574194.md)
- [MannKind Q4 revenue rises 46% as Furoscix sales surge](https://longbridge.com/en/news/277046278.md)
- [BJP's 'preparation' for Punjab polls has begun: Kejriwal as ED raids AAP MP](https://longbridge.com/en/news/282795649.md)
- [08:31 ETFirst Program Designed Specifically For Women On GLP-1 In Perimenopause Targets Muscle Loss And Metabolism After 40](https://longbridge.com/en/news/282544747.md)
- [Move Over Novo Nordisk - This Small Company Study Flags Edge In Fatty Liver Drug](https://longbridge.com/en/news/282724683.md)